Write a human plasma protein binding study report

What belongs in a human plasma protein binding report?

Identify the human-derived material, test concentrations, method and conditions used to determine binding, with the controls, variability and limitations needed to interpret the result. Distinguish a standalone ex-vivo experiment at 5.3.2.1 from binding measurements collected within an in-vivo PK study, which remain with that report.

Before you begin

In-vitro or ex-vivo human-biomaterial PK studies. Binding measurements within an in-vivo clinical PK study are reported with that clinical study.

What you will prepare: A traceable binding report with a justified material/method context and qualified interpretation of unbound exposure.

Establish the experimental system and placement

Identify whether the work uses isolated human protein, plasma, blood or another human-derived preparation, and state the PK question. M4E's 5.3.2 family concerns human biomaterials used in vitro or ex vivo for PK assessment. It does not make every experiment involving human cells a clinical report: non-PK work may belong in Module 4.

For 5.3.2.1, distinguish a standalone ex-vivo binding study from binding data collected as part of an in-vivo PK trial, which belong with the relevant 5.3.3 report. Obtain the laboratory protocol, material characterization, analytical method, source data and final assessment. Missing material identity prevents a confident applicability conclusion.

Describe what the assay can measure

As a practical reporting sequence, explain the material source and relevant characteristics, test concentrations, incubation conditions, separation method and how free and total concentrations were derived. Present the controls and checks used to distinguish protein binding from nonspecific adsorption, instability or incomplete equilibration. Report the actual evidence and laboratory acceptance rationale; do not insert universal assay limits.

Show results at the tested concentrations with variability and any material-dependent differences. Explain handling of results near quantification limits. Where an unbound fraction feeds a drug-interaction assessment, identify the exact experimental value, conditions and uncertainty used downstream. A reported number without its assay context is a weak input to a mechanistic calculation.

Review the inference before it becomes a dosing claim

Fictional exercise: a very low measured free concentration is described as proof of complete protein binding, but the assay cannot quantify below that range. The reviewer should request the method's limits and supporting recovery data, preserve the uncertainty and avoid converting a measurement limitation into an exact zero.

Compare the final binding interpretation with the clinical pharmacology summary and any model using it. If a proposed clinical conclusion concerns patients with altered protein concentrations, establish whether the experiment or other evidence represents that context. Resolve the gap through the clinical pharmacology owner; do not infer identical behavior from a healthy-donor pool alone.

Preserve the measurement limits behind the unbound fraction

Use a result interpretation sheet before a binding value enters a clinical model.

Writing exercise: the assay reports a free concentration below its quantification range. State that limit accurately rather than entering zero into a model-input table. Have the analyst establish the justified treatment of the bound or uncertain value and document its consequences.

Compare the result with its use in hepatic interaction assessments and the clinical pharmacology summary. A rounded display value should not silently become a more precise scientific claim downstream.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides